Amogastrin for the 99mTc-pertechnetate imaging of the gastric mucosa.
Most of the gastric diseases seat in the mucosa, and the present investigation was undertaken in order to see if amogastrin, a synthetic tetrapeptide, was capable of enhancing gastric accretion of intravenous 99mTc pertechnetate in man as well as in the rabbit. Improvement of gastric scintigraphy was achievable with a pretreatment of the agent by increasing the gastric accretion and reducing the background radioactivity in the liver and small intestinum.
D000328:Adult; D000818:Animals; D001417:Background Radiation; D005069:Evaluation Studies as Topic; D005260:Female; D005753:Gastric Mucosa / Q000000981:diagnostic imaging*; D006801:Humans; D008099:Liver / Q000000981:diagnostic imaging; D008875:Middle Aged; D009842:Oligopeptides / Q000494:pharmacology*; D011817:Rabbits; D011877:Radionuclide Imaging; D013670:Sodium Pertechnetate Tc 99m; D013667:Technetium
D009842:Oligopeptides; C000213:amyloxycarbonyl tetrapeptide; D013667:Technetium; D013670:Sodium Pertechnetate Tc 99m